Long-Term 5%+ Shareholder Group Exits Position Due to Estate Transfer

summarizeSummary

A long-standing 5%+ shareholder group, led by the late Carl DeSantis, has formally exited its position in Integrated BioPharma Inc. due to an estate transfer, with shares moving to a new entity controlled by his beneficiary.

check_boxKey Events

• Long-Term Shareholder Group Exits

  The group comprising Carl DeSantis, CD Financial, LLC, and CDS Group Holdings, L.L.C., which had been a beneficial owner since 2003, has formally ceased to own more than 5% of the company's common stock as of April 15, 2026.

• Ownership Transferred to Beneficiary

  The exit is a direct result of the death of Carl DeSantis in August 2023, with all shares transferred to CDDS 2.0, LLC, an entity wholly owned by his beneficiary, Damon DeSantis.

• New 5%+ Owner Emerges

  Following the transfer, CDDS 2.0, LLC and Damon DeSantis now beneficially own more than five percent of the Issuer's common stock, establishing a new significant shareholder.

auto_awesomeAnalysis

This Schedule 13D/A formally reports that Carl DeSantis, CD Financial, LLC, and CDS Group Holdings, L.L.C. (the "Group") have ceased to be beneficial owners of more than 5% of Integrated BioPharma Inc.'s common stock. The exit is a result of the death of Carl DeSantis in 2023 and the subsequent transfer of all the Group's shares to CDDS 2.0, LLC, an entity controlled by DeSantis's beneficiary, Damon DeSantis. This filing clarifies the complete ownership transition following a significant change in beneficial ownership for this micro-cap company.